Praxis Precision Medicines (PRAX) has issued an announcement.
Praxis Precision Medicines, Inc. stockholders convened at the 2024 Annual Meeting to make pivotal decisions affecting the company’s future. They elected Dean Mitchell and Jill DeSimone to the Board, endorsed Ernst & Young LLP as the independent auditor for the upcoming fiscal year, and approved both an expansion of the stock option plan by 870,000 shares and the executive compensation package. These strategic moves are set to influence the company’s governance and financial strategy, reflecting shareholder confidence and active involvement in shaping the company’s trajectory.
Find detailed analytics on PRAX stock on TipRanks’ Stock Analysis page.
